Congress targets more diverse NIH clinical trials with goals, public reporting, and outreach grants
Also known as: NIH Clinical Trial Integrity Act
Legislative Progress
Impacts
Key Points
- Sponsors of NIH-approved clinical trials would have to set clear goals to enroll and keep participants that match the disease’s patient mix (or the U.S. population if unknown).
- Trial sponsors would have to regularly share participant counts and retention rates broken out by race, ethnicity, age, and sex, with privacy limits on shared data.
- If a trial misses its diversity goals by an agreed date, the sponsor must create and then carry out a public plan (with community groups) to improve participation.
- HHS would study ways to reduce cost barriers for volunteers, like paying back out-of-pocket costs and compensating people for their time, and whether rules need updating.
- HHS and FDA would run a national education campaign and give grants to nonprofits to boost awareness and recruitment; the bill authorizes $10 million a year for 2027–2030.
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
What Happens Next
Projected impacts based on AI analysis
New NIH trial applications must include clear diversity goals and a detailed recruitment/retention plan
Sponsors may redesign studies up front (who to recruit, how to follow up, and how to reduce visit burdens). People asked to join a trial may see more flexible options like telehealth visits or local lab work.
NIH begins posting public summaries of trial diversity goals (or reasons goals aren’t needed)
Patients and advocates can more easily see whether a trial plans to include people like them, which may increase trust—or spark criticism if goals seem weak.
Sponsors start annual demographic and retention reporting to HHS/NIH while trials are running
NIH can spot early if certain groups are being left out or dropping out and push sponsors to adjust recruitment so studies better reflect real patients.
Remediation process kicks in for trials that miss agreed diversity goals
If a trial is not meeting goals, the sponsor must work with community/advocacy groups to create a public plan to fix recruitment, then put that plan into action on a deadline. This could change where and how trials recruit participants.
Comptroller General (GAO) delivers a report to Congress on barriers and challenges
Could lead to follow-up laws or agency changes focused on practical barriers like travel, time off work, mistrust, and access to trial sites.
HHS/NIH completes a study on reducing cost barriers for trial participants (reimbursements and payments)
This does not immediately change what you get paid or reimbursed, but it could set up later rule updates so participants can be repaid for travel, childcare, or time without breaking other federal rules.
National clinical trial education campaign and grant program can be funded and rolled out
You may start seeing more trial information through community groups, pharmacies, public service announcements, and provider training—especially focused on groups that have been left out of research.
Source Information
Document Type
Congressional Bill
Official Title
NIH Clinical Trial Integrity Act
Sponsor
Cosponsors
(11)Data Sources
Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.